Navigation Links
Juvaris BioTherapeutics Announces Six Scientific Presentations at Infectious Diseases Society of America (IDSA) Meeting October 6, 2007
Date:9/26/2007

Presentations to illustrate wide applicability of JuvImmune and JuvaVax

product platforms

PLEASANTON, Calif., Sept. 26 /PRNewswire/ -- Juvaris BioTherapeutics, Inc. announced today six scientific presentations at the upcoming IDSA meeting on October 6, 2007. The data will cover the consistency in multiple species of JuvImmune immunostimulant and JuvaVax products being developed for HIV, influenza, hepatitis and HSV-2.

"We are pleased that the company and its collaborators are presenting a number of high quality papers at the IDSA meeting in San Diego," said Martin D. Cleary, Co-founder, Chairman and CEO of Juvaris. "We believe these presentations demonstrate the wide applicability of the Juvaris JuvImmune and JuvaVax vaccine platforms for prophylaxis and treatment of infectious disease."

About Juvaris

Juvaris BioTherapeutics was created in 2003 to develop an immunotherapeutic product platform for the treatment of infectious diseases and cancers using lipid-DNA complexes. Cationic lipids are formulated with non-coding DNA (plasmid) to create the JuvImmune Immunostimulant, a lipid-DNA complex, which as a single product will have utility in multiple infectious disease and cancer applications. The JuvImmune product has been shown to be at least 50-times more potent at triggering innate immune activation and interferon release than current immune stimulants.

When combined with disease-specific antigens, the technology creates JuvaVax vaccines capable of activating substantial antibody- and cell-mediated immune responses, particularly induction of cytotoxic T lymphocytes (CTL). Immunological responses elicited by the lipid-DNA complexes have been successfully demonstrated in both prophylactic and therapeutic settings in a variety of mammals including rodents, rabbits, cats, dogs and non-human primates. This platform provides the opportunity to develop many disease-specific immunotherapy products, for which
'/>"/>

SOURCE Juvaris BioTherapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... DUBLIN , Aug. 27, 2014 ... the "Global Enzyme for Pulp & Paper Industry ... The Global Enzyme for Pulp & Paper Industry ... the current state of the global enzyme for pulp ... basic overview of the industry including definitions, classifications, applications ...
(Date:8/27/2014)... , Aug. 27, 2014  ARCH Venture ... firms investing in the development of seed and ... eighth venture fund closed with more than $400 ... its $250 million subscription target by more than ... VIII shows the strength and potential of our ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 Riviera ... is announcing the creation of the Sancilio Scientific ... take the SCI’s philosophy of looking to nature ... and development actions are based on sound scientific ... Scientific Advisory Board provides a vehicle for SCI ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 After the ... reason that the next beverage craze is going to ... today that formulators can use Stress Relief energy pattern ... in the making of a beverage, including minerals, herbs ... stress-generated energy, channeling that power into rapid recovery and ...
Breaking Biology Technology:Global Enzyme for Pulp & Paper Industry Report 2014 2Latest ARCH Venture Partners Fund Closes Above $400 Million 2Latest ARCH Venture Partners Fund Closes Above $400 Million 3New Sancilio & Company, Inc. Scientific Board 2New Sancilio & Company, Inc. Scientific Board 3Stress Relief: 1 Way to De-Stress Your Beverage Formula 2Stress Relief: 1 Way to De-Stress Your Beverage Formula 3Stress Relief: 1 Way to De-Stress Your Beverage Formula 4
... April 15 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX:,MS), ... sclerosis (MS), today,announced that the independent Data Safety ... on-going MAESTRO-03 U.S. pivotal phase III,clinical trial of ... and,recommended that the trial continue., This was ...
... Bionovo Inc.,(Nasdaq: BNVI ) will present findings on ... BN107 and BN108 at the American Association of,Cancer Research ... in San,Diego, CA, April 12 - 16, 2008., ... cell,apoptosis (cell death) induced by BN107 and BN108. As ...
... ST. JOSEPH, Mich., April 15 GeneGo, Inc., ... The Scripps,Translational Science Institute has joined the MetaMiner ... build the first systems,biology and pathway analysis platform ... will vote on deliverables that will include,disease specific ...
Cached Biology Technology:BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board 2Bionovo to Present Recent Findings of BN107 and BN108, Its Anticancer Agents, at the American Association of Cancer Research 2The Scripps Translational Science Institute Joins The MetaMiner Cardiac Consortium 2
(Date:8/27/2014)... of studies have shown that excessive iron ... Parkinson,s disease. Previous studies from Chunyan Guo ... China have shown that baicalin prevented iron ... metal transporter 1 expression, and increased ferroportin ... rotenone-induced Parkinson,s disease rats. However, the relationship ...
(Date:8/27/2014)... that can be found in both unprocessed and processed ... Denmark have been infected with Listeria from ... The bacterium is notoriously difficult to fight because it ... in its surroundings, says Associate Professor Birgitte Kallipolitis, University ... of Biochemistry and Molecular Biology, she has published a ...
(Date:8/26/2014)... over a colony of harmful bacteria, biofilms make ... protected in a biofilm pose a significant health ... to treatment, and biofilm-protected bacteria account for some ... and are 50 to 1,000 times more resistant ... essence, we may have stumbled onto a magic ...
Breaking Biology News(10 mins):Researchers discover why Listeria bacterium is so hard to fight 2Researchers discover why Listeria bacterium is so hard to fight 3Breakthrough antibacterial approach could resolve serious skin infections 2Breakthrough antibacterial approach could resolve serious skin infections 3
... energy produced by cars, machines, and industry around the world ... but researchers have found a new way to make "thermoelectric" ... amounts of energy. And it,s based on a device ... Chemists at Oregon State University have discovered that simple ...
... team has turned their newly developed 3-D microscope technology ... use. U of A engineering professor Dileepan ... system called Virtual Reflected-Light Microscopy. The technology consists of ... that moves the objects being photographed and software programs ...
... Paul Kenis and James Slauch have been named ... university,s most talented teachers, scholars and researchers. Kenis, ... in the field of micro fluidics and the development ... health. These tools include the creation of evaporation-based ...
Cached Biology News:Microwave ovens a key to energy production from wasted heat 2Microwave ovens a key to energy production from wasted heat 3University of Illinois faculty members named University Scholars 2
Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
TRIzol Reagents are ready-to-use monophasic solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA DNA and proteins (16)....
...
Biology Products: